Amparore D, Fiori C, Valerio M, et al. - This study was sought to present the 3-year outcomes of a prospective, single-arm, multicenter, international clinical study with the second generation of the temporary implantable nitinol device (iTIND; Medi-Tate Ltd, Israel) on men suffering lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). Between December 2014 and December 2016, researchers included a total of 81 men with symptomatic BPO (IPSS ≥ 10, peak urinary flow < 12 ml/s, and prostate volume < 75 ml). The study found that at 3 years of follow-up, treatment of BPO-related LUTS with iTIND demonstrated a significant and durable reduction in symptoms and improvement of functional parameters and quality of life. Between 24 and 36 months, there were no late postoperative complications, ejaculatory dysfunction, or additional treatment failures.